Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001243986 | SCV001417178 | uncertain significance | Charcot-Marie-Tooth disease type 4 | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 404 of the SBF2 protein (p.Leu404Phe). This variant is present in population databases (rs764058215, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SBF2-related conditions. ClinVar contains an entry for this variant (Variation ID: 968773). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002357040 | SCV002653582 | uncertain significance | Inborn genetic diseases | 2024-12-03 | criteria provided, single submitter | clinical testing | The c.1210C>T (p.L404F) alteration is located in exon 12 (coding exon 12) of the SBF2 gene. This alteration results from a C to T substitution at nucleotide position 1210, causing the leucine (L) at amino acid position 404 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004793349 | SCV005412292 | uncertain significance | not provided | 2024-07-19 | criteria provided, single submitter | clinical testing | PM2 |